Vestal Point Capital, LP Verve Therapeutics, Inc. Transaction History
Vestal Point Capital, LP
- $1.34 Trillion
- Q2 2024
A detailed history of Vestal Point Capital, LP transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Vestal Point Capital, LP holds 500,000 shares of VERV stock, worth $2.49 Million. This represents 0.18% of its overall portfolio holdings.
Number of Shares
500,000Holding current value
$2.49 Million% of portfolio
0.18%Shares
1 transactions
Others Institutions Holding VERV
# of Institutions
173Shares Held
74.7MCall Options Held
115KPut Options Held
144K-
Alphabet Inc. Mountain View, CA12.3MShares$61.5 Million3.79% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$33 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$26.2 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.53MShares$22.6 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.87MShares$19.3 Million0.01% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $299M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...